drugset / Trial / NCT06583031
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
RandomizedParallel-groupTriple-blindPrevention
Summary
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
Timeline
- Start
- 2024-10-09
- Primary completion
- 2025-10-09
- Completion
- 2025-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monovalent RSV Vaccine | Vaccine | — | Intramuscular |
| Subject | RSV/hMPV vaccine | Vaccine | — | Intramuscular |